Genmab announces patent settlement agreement for ofatumumab

GSK enters patent settlement with Genentech regarding ofatumumab

28-Mar-2012 - Denmark

Genmab A/S announced that GlaxoSmithKline (GSK) has agreed a settlement with Genentech Inc. and City of Hope (a California not-for-profit organization) concerning two U.S. patents that relate to recombinant antibody production for ofatumumab. GSK is Genmab’s development and commercial collaborator for the CD20 antibody ofatumumab. The dispute concerned U.S. Patents No 6,331,415 and U.S. No 7,923,221 (the Cabilly II and Cabilly III patents) issued to Genentech, Inc. and City of Hope. No further terms of the settlement are disclosed.

The case was initiated by GSK in October 2009 and has been pending before the United States District Court for the Central District of California. The settlement means that the pending court case will now be concluded. The two patents are due to expire in December 2018.

The settlement is not expected to affect Genmab's financial guidance for 2012.

Other news from the department politics & laws

Most read news

More news from our other portals

So close that even
molecules turn red...